23 results about "Deferoxamine" patented technology

The invention discloses a preparation method and application of a novel hybrid extracellular vesicle. According to the invention, vesicles derived from endothelial cells and neutrophil cells are combined with deferoxamine, and a biological mixed nano vesicle platform (DFO (HEVS)) is developed to solve the problem of diabetes wound healing. According to the dual-targeting system, DFO is accurately delivered to a wound part by utilizing CXCR4 mediated endothelial cell homing and beta2 integrin dependent inflammation tropism, DFO (at) HEVs activates and recovers vascular regeneration through HIF-1alpha / VEGF, ferroptosis is inhibited through Nrf2 / GPX4 signal transduction, macrophages are reprogrammed into a repair promoting M2 phenotype, and oxidative stress-inflammation-ferroptosis circulation is effectively broken.

The invention discloses injectable hydrogel with a myocardial tissue repairing function as well as a preparation method and application of the injectable hydrogel, and relates to the technical field of medical materials. The preparation method of the injectable hydrogel comprises the following steps: carrying out a reaction on deferoxamine and DSPE-PEG-NHS, so as to obtain DSPE-PEG-DFO; the preparation method comprises the following steps: wrapping carvedilol with DSPE-PEG-DFO under the hydrophilic and hydrophobic action, so as to obtain a drug-loaded nano-micelle; the preparation method comprises the following steps: reacting a polymer containing amino or hydroxyl with methacrylic anhydride to obtain a methylacryloyl modified polymer; reacting the carboxyl-containing polymer with cysteamine hydrochloride to obtain a sulfydryl modified polymer; mixing the drug-loaded nano-micelle, the methylacryloyl modified polymer and the sulfydryl modified polymer, and reacting under ultraviolet radiation to obtain the injectable hydrogel. The hydrogel disclosed by the invention is good in biocompatibility, can release deferoxamine and carvedilol in a ladder manner, is matched with a myocardial repair process, and realizes a function of repairing damaged myocardial tissues.

The invention relates to a touch fluid neuron specific tracing imaging agent, a preparation method and application, and belongs to the technical field of nuclear medicine imaging, the tracing imaging agent is composed of a nerve tracer agent horseradish peroxidase (HRP), zirconium-89 isotope chelated by deferoxamine and a pharmaceutically acceptable carrier, the effective tracking window of the tracer agent is prolonged to 120 hours, and the effective tracking window of the tracer agent is prolonged to 120 hours. The multi-stage synaptic transfer period of the fluid touching neuron can be completely covered; the spatial resolution is improved by 5-8 times compared with that of traditional FDG-PET, and a fluid touching neuron cluster can be accurately presented; the in-vitro serum stability is excellent, the radiochemical purity is still larger than or equal to 80.5% within 120 hours, PET / MRI bimodal imaging can be adapted, drug administration is conducted through lateral ventricle minimally invasive injection, the probe is suitable for various animal models such as mice, rats and non-human primates, in-vivo dynamic tracing of sympathetic fluid neuron trans-synapses can be achieved on the premise that no tissue damage exists, and the probe has a good application prospect. And a key technical tool is provided for neural circuit analysis, neuroscience basic research and preclinical research of neurodegenerative diseases.

The application relates to a preparation method and application method of a mesenchymal stem cell protective agent composition, and relates to the technical field of stem cell treatment, in particular to a protective agent composition, a preparation technology of the protective agent composition and an application technology of the protective agent composition in mesenchymal stem cell treatment. The application solves the problems of insufficient cell stemness maintenance, complex formula or cell toxicity in the existing mesenchymal stem cell cryopreservation. The protective agent composition prepared by the preparation method comprises a deferoxamine pretreatment protective agent and a sodium lactate Ringer injection storage solution. The application method inhibits low-temperature-induced ferroptosis through DFO pretreatment, so that the mesenchymal stem cells can still maintain the multi-directional differentiation potential, the immunoregulatory function and the proliferation ability after being treated at 4 DEG C for 24-48 hours, the serum or complex nutritional ingredients do not need to be added, and the protective agent composition has the advantages of clear composition, high safety, simple operation and the like. The application is suitable for the fields of stem cell treatment, regenerative medicine, pet medical treatment and the like.

The invention discloses a quantitative method for detecting trace free chelate deferoxamine in ACCs medicine based on reversed phase chromatography. The quantitative method comprises the following steps: preparing a deferoxamine standard substance solution; the method comprises the following steps: respectively detecting a sample to be detected and a deferoxamine standard substance solution by adopting a liquid chromatograph under the detection conditions that a chromatographic column is PLRP-S (2.1 * 100 mm, 5 [mu] m), the column temperature is 25-80 DEG C, and a filler is PS / DVB porous particles; mobile phases: a phase A is an aqueous solution containing organic acid, and a phase B is an organic solvent containing organic acid; establishing a calibration curve according to the concentration of the standard deferoxamine solution and the peak area of the corresponding elution peak, and then substituting the peak area of the elution peak of the sample to be detected into the calibration curve to obtain the concentration of the deferoxamine in the sample to be detected. According to the method, the tedious sample pretreatment step is omitted, the direct sample injection analysis of the sample is realized, the experimental period is greatly shortened, and the detection efficiency is improved.

The invention discloses an amphiphilic lipid compound derived from deferoxamine. The invention also discloses a lipidosome nano composition assembled by the compounds, and application of the lipidosome nano composition in preparation of drugs and treatment of iron overload diseases and tumors.

The invention discloses a layered microneedle patch as well as a preparation method and application thereof, and belongs to the field of biological medicines. Wherein the needle body tip is composed of a therapeutic agent and L-arginine shell modified glycan gel, has excellent biocompatibility and free DNA removal ability, and can deliver deferoxamine and synergistically regulate and control inflammation signals; the upper part of the needle body and the substrate are made of low-molecular-weight hyaluronic acid which is quickly dissolved after being in contact with skin, so that the needle tip is quickly separated from the substrate, the needle tip is retained at a diseased region, and effective deposition of a medicine at the diseased region is ensured; the layered microneedle can slowly release deferoxamine through pH response so as to inhibit ferroptosis; the modified chitosan can efficiently remove free DNA so as to reduce immune inflammation and cooperatively block immune inflammation circulation. The preparation process of the layered microneedle is controllable, the material biocompatibility is excellent, and the layered microneedle has the advantages of efficient targeted delivery, long-acting release and synergistic treatment, so that a feasible strategy is provided for psoriasis treatment.

The invention discloses photo-thermal controlled-release injectable hydrogel for promoting wound healing through nerve and blood vessel synergistic regeneration as well as a preparation method and application of the photo-thermal controlled-release injectable hydrogel. The preparation method comprises the following steps: preparing an ovalbumin electrostatic spinning fiber membrane; the preparation method comprises the following steps: modifying an ovalbumin electrostatic spinning fiber membrane with dopamine, grafting deferoxamine, and shearing and grinding to obtain the drug-loaded short fiber capable of providing a topological structure to guide cell growth; the preparation method comprises the following steps: mixing drug-loaded short fibers with a multi-walled carbon nanotube dispersion liquid, preparing micro-droplets through a microfluidic device, and carrying out cross-linking curing to obtain photothermal responsive drug-loaded short fiber microspheres; the preparation method comprises the following steps: blending an ovalbumin hydrogel precursor solution with photo-thermal responsive drug-loaded short fiber microspheres, and carrying out catalytic molding through a cross-linking agent under a heating condition. According to the invention, the photo-thermal response microspheres are combined with the hydrogel, so that the regeneration microenvironment is synergistically regulated and controlled by multiple factors, and a new thought is provided for tissue engineering nerve grafts. The method has the characteristics of no toxicity, harmlessness, environmental protection, simplicity, feasibility and easiness in operation.

This application relates to the field of biomedical technology, specifically disclosing a therapeutic probe targeting neuroblastoma GD2, adapted to the clinical needs of relapsed, refractory, and high-risk neuroblastoma. This therapeutic probe comprises paired diagnostic and therapeutic components, both using the humanized anti-GD2 monoclonal antibody hu3F8 as the sole targeting carrier; the diagnostic component is a zirconium-89-labeled deferoxamine-hu3F8 conjugate, and the therapeutic component is an actinium-225-labeled DOTA-hu3F8 conjugate. This application also discloses its preparation method, obtaining a high-purity product through three steps: antibody-chelating agent conjugation, radionuclide labeling, and purification. This probe system can be used to prepare a therapeutic drug composition for neuroblastoma, exhibiting strong targeting specificity, enabling imaging-guided precise radioimmunotherapy, and demonstrating good synergistic diagnostic and therapeutic effects.

The invention discloses application of DFO and a composition thereof in functional recovery after ovarian transplantation. It is found for the first time that deferoxamine (DFO) can effectively improve the survival rate of follicles, increase the number of follicles and recover the functional structure of an ovary. In addition, it is found for the first time that the combination of DFO and vascular endothelial growth factor A (VEGF-A) has a synergistic effect on functional recovery after ovarian transplantation. The invention provides an effective drug and a drug combination strategy for functional recovery after ovarian transplantation, and has a wide application prospect in the technical field of development of repair drugs after ovarian transplantation.

The present application relates to the technical field of biological medicine, and particularly relates to a tumor microenvironment responsive iron overload hydrogel, a preparation method and application thereof. The hydrogel anchors deferoxamine conjugate in the hydrogel network through thiol-maleimide click chemistry, does not affect intracellular Fe 2+ The Fenton reaction process occurs, and the excreted Fe 3+ is specifically captured and locked, iron ion loss and systemic diffusion are effectively prevented, and a long-acting iron overload microenvironment is constructed locally in the tumor; iron oxide nanoparticles release Fe 2+ in response to a weak acid microenvironment, hydroxyl radicals are catalytically generated, and the effect of the iron death inducer on the antioxidant pathway is synergistic, effectively inducing tumor cell ferroptosis and overcoming treatment resistance; the hydrogel has excellent biocompatibility, blood compatibility and targeted tumor inhibition activity, inhibits the growth of solid tumors while reducing systemic toxic side effects, and thus realizes efficient and safe local treatment of tumors.

The application discloses a novel preparation method and application of hybrid extracellular vesicles. The application combines endothelial cell-derived and neutrophil-derived vesicles with deferoxamine to develop a biological mixed nano-vesicle platform (DFO@HEVs) to solve the problem of diabetic wound healing. The dual-targeting system utilizes CXCR4-mediated endothelial cell homing and beta2 integrin-dependent inflammatory tropism to accurately deliver DFO to the wound site, DFO@HEVs activate HIF-1alpha / VEGF to restore vascular regeneration, inhibit ferroptosis through Nrf2 / GPX4 signaling, and reprogram macrophages into a pro-repair M2 phenotype, effectively breaking the oxidative stress-inflammation-ferroptosis cycle.

The invention discloses application of DFO and a composition thereof in functional recovery after ovarian transplantation. It is found for the first time that deferoxamine (DFO) can effectively improve the survival rate of follicles, increase the number of follicles and recover the functional structure of an ovary. In addition, it is found for the first time that the combination of DFO and vascular endothelial growth factor A (VEGF-A) has a synergistic effect on functional recovery after ovarian transplantation. The invention provides an effective drug and a drug combination strategy for functional recovery after ovarian transplantation, and has a wide application prospect in the technical field of development of repair drugs after ovarian transplantation.

The invention relates to the technical field of animal husbandry, in particular to an inhibitor for weaned piglet intestinal ferroptosis caused by vomitoxin and a preparation method, an iron chelating agent (deferoxamine and DFO), a GPX4 activator (selenomethionine and SeMet) and anti-inflammatory components (curcumin, astragalus polysaccharide and dihydroartemisinin) are integrated, and three major ferroptosis core pathways such as iron accumulation, GPX4 inactivation and lipid peroxidation are covered; meanwhile, the components are coated with pH-sensitive chitosan-sodium alginate nano-particles, so that the components can pass through the stomach and are prevented from being damaged by gastric acid, it is ensured that the medicine is accurately released in the alkaline environment of the intestinal tract, and therefore the utilization rate of the medicine is increased; moreover, the selenomethionine, the curcumin, the astragalus polysaccharide and the dihydroartemisinin are all natural sources, so that the risk of chemical drug residues can be avoided, and the selenium methionine, the curcumin, the astragalus polysaccharide and the dihydroartemisinin can be used as a feed additive to be applied to weaned piglets.

The application discloses a preparation method of a 3D printing cerium hydroxyapatite bone repair scaffold material, and comprises the following steps: adding phenyl (2, 4, 6-trimethylbenzoyl) lithium phosphate salt powder into manganese-chelated deferoxamine grafted methylacryl gelatin, stirring, adding cerium hydroxyapatite nanowires which are surface-modified by citric acid, and stirring to obtain 3D printing slurry; and the 3D printing slurry is extruded by a 3D printer while being cross-linked by 365nm ultraviolet irradiation to obtain the 3D printing cerium hydroxyapatite bone repair scaffold material; the material has good biocompatibility, can promote vascularization and immune regulation, and can effectively regulate M2 phenotype differentiation of RAW264.7, so that more BMP-2 and PDGF-bb growth factors are secreted, osteogenesis differentiation and angiogenesis are promoted, and bone defect repair is promoted from the perspective of immune regulation.

Described herein are semi-solid formulations comprising a gelling agent, solubilizer, and deferoxamine or a pharmaceutically acceptable sale thereof that can be used to prevent or mitigate skin injuries incurred during radiation therapy. In certain examples the formulations may be applied before radiation exposure to one or more of skin at, adjacent to, or between entry and exit sites of a beam of radiation configured to be directed at or through a patient's body.

The invention provides an umbilical cord mesenchymal stem cell factor for a medicine and a preparation method thereof, and belongs to the technical field of biology, and the preparation method comprises the following steps: carrying out induced culture by adopting third-generation amplified cells of umbilical cord mesenchymal stem cells; the induction culture medium contains epidermal growth factors, vascular endothelial growth factors, deferoxamine, vitamin C, rapamycin, asiaticoside, astragaloside, astragalus polysaccharide and the like, secretion of target factors is effectively promoted, cell differentiation is controlled, two chromatographic columns are adopted for purification and extraction, the obtained product is high in yield and purity, and the effect of the product is further improved.

The application provides a medicine umbilical cord mesenchymal stem cell factor and a preparation method thereof, belongs to the biotechnology field, and the preparation method comprises the following steps: inducing and culturing the third generation of expanded cells of umbilical cord mesenchymal stem cells, the induction culture medium contains epidermal growth factor, vascular endothelial growth factor, deferoxamine, vitamin C, rapamycin, asiaticoside, astragaloside IV, astragalus polysaccharide and the like, the secretion of the target factor is effectively promoted, cell differentiation is controlled, two kinds of chromatography columns are used for purification and extraction, the product yield is high, the purity is high, and the efficacy of the product is further improved.

The invention discloses biomimetic catalytic nano-particles, a preparation method thereof and application of the biomimetic catalytic nano-particles in preparation of cerebral hemorrhage treatment drugs, and belongs to the technical field of biomedical nano-particles. The preparation method comprises the following steps: S1, preparing a mixed solution A by taking polybasic carboxylate and monobasic carboxylate as raw materials; s2, uniformly mixing a ceric ammonium nitrate solution, a heme oxygenase-1 solution and a deferoxamine solution to obtain a mixed solution B; s3, mixing and stirring the mixed solution A and the mixed solution B to prepare the biomimetic catalytic nanoparticles. The preparation method is simple and mild in condition, the prepared biomimetic catalytic nano-particles have efficient focus targeting performance, the multi-mechanism synergistic treatment effect of hematoma toxicity (removing heme, iron and ROS) and tissue repair (promoting angiogenesis and neuroprotection) is achieved at the same time, and the biomimetic catalytic nano-particles are remarkable in clinical treatment effect and excellent in biological safety and have good application prospects. Good clinical transformation prospects are realized.

The invention relates to a hyperxic lung injury treatment medicine based on ferroptosis inhibition, a screening method and application, and relates to the technical field of biological medicines. The application has the advantages that ferroptosis is one of key mechanisms of high-oxygen lung injury, a new target spot is provided for clinical prevention and treatment, and in-vivo and in-vitro experiments prove that high oxygen can induce mouse lung microvascular endothelial cells to generate ferroptosis, high oxygen can induce mice to generate acute lung injury, and ferroptosis participates in the process; the ferroptosis related signal path is activated in the hyperxia lung injury; the ferroptosis inhibitor (such as dexmedetomidine, Liproxstatin-1 and deferoxamine) can be used for remarkably relieving the cell injury induced by high oxygen and the pathological change of lung tissues. The target spot and the biomarker provided by the invention can be used for developing a diagnostic kit for evaluating the severity or prognosis of HALI, and the established screening model and method can be used for high-throughput screening of novel anti-HALI compounds to accelerate the research and development process of new drugs.

The invention belongs to the technical field of organic synthesis, and particularly relates to a diquafosol sodium purification method which comprises the following steps: S1, dissolving a material, S2, eluting a solution obtained in the step S1 by using an elution solvent through a low-pressure preparation system filled with filler, and collecting a product component containing diquafosol sodium, and S3, carrying out nanofiltration concentration on the product component collected in the step S2, so as to obtain the diquafosol sodium. S4, adding ethanol into the concentrated solution for crystallization, and then filtering to obtain diquafosol sodium crystals; S5, drying, and recovering and reusing waste liquid through nanofiltration (such as cyclic utilization of the elution solvent), so that the waste liquid discharge and the use amount of a fresh solvent are reduced, the method is environment-friendly and economical, the elution solvent without strong acidity is adopted, and the cost is reduced. Equipment corrosion is avoided, the service life of production equipment is prolonged, and meanwhile, the consistency among batches is ensured through a gradient elution procedure and crystallization parameter optimization.

Modified hydrophilic carbon clusters (HCCs), poly(ethylene glycol)-hydrophilic carbon clusters (PEG-HCCs) and similarly structured materials like graphene quantum dots (GQDs), PEGylated GQDs, small molecule antioxidants, and PEGylated small molecule antioxidants. These materials have been modified with an iron chelating moiety, deferoxamine, or a similar chelating moiety. By exploiting common binding sites, the carbon nanostructure facilitates intracellular transport including in mitochondria, reduces oxidative breakdown of the chelator moiety prior to treatment, and reduces both the cause and consequences of metal induced oxidative stress within the body thus providing a novel form of therapy for a range of oxidative and metal-related toxicities. Graphenic materials can be used for the treatment of acute and chronic mitochondrial electron transport chain dysfunction.

The application discloses a facial filling and lip sculpting method based on a pre-expanding autologous fat pad principle, belongs to the technical field of medical cosmetology and biological tissue engineering, and comprises the following steps: preparing a biological scaffold with a vascularization induction function, and the preparation raw material of the biological scaffold comprises the following components in parts by weight: 80-100 parts of polycaprolactone, 20-30 parts of gelatin, 5-10 parts of dopamine hydrochloride, 2-4 parts of deferoxamine, 3-6 parts of a zwitterionic polymer, 1-3 parts of an activator, 1000-1500 parts of an organic solvent and 500-800 parts of a tris-hydroxymethyl aminomethane-hydrochloric acid buffer solution. The thin film and high porosity are combined, so that the newly generated blood vessels can smoothly penetrate the scaffold and go deep into the interior, the blood supply dead angle in the central region is eliminated, and the probability of fat liquefaction and necrosis is reduced.